CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $239.85M, lower than 95% of all stocks globally
- PositionOperating margin is -5007%, lower than 95% of its Biotechnology peers (median -38%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
239.85MUSDvs all stocks (USD)
Revenue (TTM)
4.69MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.2510xvs all stocks
52-Week Change
5.14%vs all stocks
Market Capitalization
239.85MUSDvs all stocks (USD)
Enterprise Value
47.65MUSDvs all stocks (USD)
Forward P/E
-2.05xvs Biotechnology peers
Price to Sales (TTM)
51.18xvs Biotechnology peers
Price to Book (MRQ)
0.9516xvs Biotechnology peers
Enterprise to Revenue
10.17xvs Biotechnology peers
Enterprise to EBITDA
-0.2790xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-29.20%vs Biotechnology peers
Return on Equity (TTM)
-54.10%vs Biotechnology peers
Revenue (TTM)
4.69MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1120USDUpdated Sep 28, 2026Quarterly Revenue Growth
-53.90%vs Biotechnology peers
Gross Profit (TTM)
-134.36MUSDvs all stocks (USD)
EBITDA (TTM)
-170.86MUSDvs all stocks (USD)
Net Income (TTM)
-165.78MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-53.95%vs Biotechnology peers
Operating Cash Flow (TTM)
-134.67MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-77.67MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
25.42MUSDFY2025 · Dec 31, 2025Operating Income
-157.90MUSDvs all stocks (USD)
Pre-tax Income
-142.83MUSDFY2025 · Dec 31, 2025Income Tax Expense
924.00KUSDFY2025 · Dec 31, 2025Net Income
-143.75MUSDFY2025 · Dec 31, 2025EBIT
-157.90MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-153.80MUSDFY2025 · Dec 31, 2025Research & Development
142.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.05MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
15.07MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.47USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.47USDFY2025 · Dec 31, 2025Basic Shares Outstanding
41.37MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
41.37MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-143.75MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-136.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
-137.60MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
94.34MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.70MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-143.75MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
4.10MUSDFY2025 · Dec 31, 2025Stock-based Compensation
19.61MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.50MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.80MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.22MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.04MUSDFY2025 · Dec 31, 2025Purchase of Investments
-141.61MUSDFY2025 · Dec 31, 2025Sale of Investments
259.46MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
116.81MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
38.94MSharesUpdated Sep 28, 2026Float Shares
20.10MSharesUpdated Sep 28, 2026Shares Short
2.74MSharesUpdated Sep 28, 2026Short Ratio
9.74daysvs all stocks
Short % of Shares Outstanding
10.94%vs all stocks
% Held by Insiders
12.23%vs all stocks
% Held by Institutions
82.11%vs all stocks
Total Cash (MRQ)
223.00MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.18USDUpdated Sep 28, 2026Total Debt (MRQ)
48.54MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2080xvs Biotechnology peers
Current Ratio (MRQ)
10.89xvs Biotechnology peers
Book Value per Share (MRQ)
6.47USDUpdated Sep 28, 2026Total Assets
377.38MUSDvs all stocks (USD)
Total Current Assets
306.25MUSDFY2025 · Dec 31, 2025Total Liabilities
71.25MUSDFY2025 · Dec 31, 2025Total Non-current Assets
71.13MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
46.79MUSDFY2025 · Dec 31, 2025Total Current Liabilities
24.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
90.39MUSDFY2025 · Dec 31, 2025Other Short-term Investments
205.30MUSDFY2025 · Dec 31, 2025Accounts Payable
2.29MUSDFY2025 · Dec 31, 2025Short-term Debt
4.14MUSDFY2025 · Dec 31, 2025Deferred Revenue
342.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.17MUSDFY2025 · Dec 31, 2025Long-term Debt
46.79MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-273.09MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
306.13MUSDvs all stocks (USD)
52-Week Low
5.55USDUpdated Sep 28, 202652-Week High
16.45USDUpdated Sep 28, 202652-Week Change
5.14%vs all stocks
Beta
-0.2510xvs all stocks
50-Day MA
6.91USDUpdated Sep 28, 2026200-Day MA
9.45USDUpdated Sep 28, 2026Avg 10-Day Volume
303.16KSharesUpdated Sep 28, 2026Avg 30-Day Volume
286.83KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-3.96USDUpdated Sep 28, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -5007%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -50.07Industry median: -0.38Industry P5: -43.63Peers compared: 260
Price-to-book is 0.95×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.95Industry median: 2.86Industry P5: 0.98Peers compared: 260
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 10.89Altman Z-Score: 0.59
Financial Health
Altman Z-Score 0.59: distress zoneCritical
Altman Z-Score: 0.59
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $239.85M, lower than 95% of all stocks globallySignificant
Market cap (USD): 239,849,881Global P5: 275,556,405.438
Revenue is $4.69M, lower than 95% of all stocks globallySignificant
Revenue (USD): 4,686,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immunotech Biopharm Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Niagen Bioscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Lyell Immunopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Sionna Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Wave Life Sciences Ltd.
2 interpretationsDecline With Range Expansion And DrawdownHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Inventage Lab Inc.
2 interpretationsDecline With Range Expansion And DrawdownHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Voronoi, Inc.
2 interpretationsDecline With Range Expansion And DrawdownHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC